Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target.

Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. Clin Cancer Res. 2012 Jul 15; 18(14):3737-42.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.